Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
4.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Novel Small-Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects.

Cancer medicine·2026
Same author

Targeting fibroblast activation protein in solid tumors via LNP-mediated CAR-mRNA delivery promotes durable regression in murine models.

Scientific reports·2025
Same author

Deficiencies in methionine, tryptophan, and niacin remodels intestinal transcriptome and gut microbiota in female mice.

Scientific reports·2025
Same author

Antisense oligonucleotide targeting nicotinamide N-methyltransferase exhibits antitumor effects.

Molecular therapy. Nucleic acids·2025
Same author

In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines.

International journal of molecular sciences·2025
Same author

Recent Exploration of Solid Cancer Biomarkers Hidden Within Urine or Blood Exosomes That Provide Fundamental Information for Future Cancer Diagnostics.

Diagnostics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Mar 26, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K

[CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY].

Masamitsu Konno, Hideshi Ishii, Yuichiro Doki

    Nihon Geka Gakkai Zasshi
    |February 6, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Small noncoding ribonucleotides, including microRNAs, can reprogram cancer cells. These molecules offer a potential new strategy for treating human cancers by modulating malignant phenotypes.

    More Related Videos

    Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
    07:08

    Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

    Published on: February 2, 2024

    1.6K
    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
    07:29

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

    Published on: June 20, 2015

    20.3K

    Related Experiment Videos

    Last Updated: Mar 26, 2026

    Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
    10:04

    Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

    Published on: August 1, 2025

    1.9K
    Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
    07:08

    Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

    Published on: February 2, 2024

    1.6K
    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
    07:29

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

    Published on: June 20, 2015

    20.3K

    Area of Science:

    • Epigenetics
    • Molecular Biology
    • Cancer Biology

    Context:

    • Cancer's genetic basis is complicated by epigenetic alterations influencing initiation and progression.
    • Small noncoding ribonucleotides, specifically microRNAs, have been shown to induce cellular reprogramming.
    • MicroRNA200c, -302s, and -369 are key players in these epigenetic modifications.

    Purpose:

    • To investigate the role of specific microRNAs (microRNA200c, -302s, -369) in cancer cellular reprogramming.
    • To explore how these microRNAs modulate the malignant phenotypes of human cancer cells.
    • To assess the therapeutic potential of delivering functional small-sized ribonucleotides for cancer treatment.

    Summary:

    • Introduction of microRNA200c, -302s, and -369 induces cellular reprogramming in cancer cells.
    • MicroRNA200c inhibits epithelial-mesenchymal transition, a key process in cancer metastasis.
    • MicroRNA302s promotes tumor suppressor gene expression by demethylating promoter regions.
    • MicroRNA369 alters cancer cell metabolism, impacting tumor growth and survival.

    Impact:

    • These microRNAs reprogram cancer cells, suggesting a novel therapeutic avenue.
    • Modulating cancer cell metabolism and epithelial-mesenchymal transition offers new targets for intervention.
    • The findings support the development of small ribonucleotide-based therapies for human cancers.